Please check your internet connection and try again.
# Clobazam (Oral Formulation)
## Overview
Clobazam is a 1,5-benzodiazepine with a unique chemical structure that results in reduced sedative effects compared to 1,4-benzodiazepines (e.g., diazepam, lorazepam). It acts as a positive allosteric modulator of the $\text{GABA}_A$ receptor.
## Primary Indications
* Adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS).
## Adult Dosing
* **Initial:** 10 mg/day. Increase gradually over 2 weeks to the recommended dose of 20 mg/day.
* **Maximum:** 40 mg/day (administered in divided doses twice daily).
* **Note:** Dosing is weight-based for patients $\leq$ 30 kg.
## Pediatric Dosing (Patients $\geq$ 2 years)
* **Weight $\leq$ 30 kg:**
* Initial: 5 mg/day.
* Target: 10 mg/day after 1 week.
* Maximum: 20 mg/day.
* **Weight > 30 kg:**
* Initial: 10 mg/day.
* Target: 20 mg/day after 1 week.
* Maximum: 40 mg/day.
* **Administration:** Doses should be given twice daily. For patients unable to swallow tablets, the tablet can be crushed and mixed with applesauce, or the oral suspension should be used.
## Dose Adjustments
* **Hepatic Impairment:** Reduce starting dose by 50%. Increase slowly as tolerated.
* **Renal Impairment:** No specific adjustment recommendation, but use caution as some metabolites are renally excreted.
* **CYP2C19 Poor Metabolizers:** Use caution; plasma concentrations of the active metabolite (N-desmethylclobazam) may be significantly higher.
## Contraindications
* Known hypersensitivity to clobazam or product components.
## Adverse Effects
* **Common:** Somnolence, pyrexia, lethargy, drooling (sialorrhea), constipation, ataxia, behavioral changes (aggression, irritability).
* **Serious:** Severe dermatological reactions (Stevens-Johnson syndrome/TEN), respiratory depression, physical dependence and withdrawal, suicidal ideation.
## Key Drug Interactions
* **CNS Depressants:** Enhances sedative, respiratory, and hypotensive effects of opioids, alcohol, and other CNS depressants.
* **CYP2C19 Inducers/Inhibitors:** Strong inhibitors (e.g., fluconazole, omeprazole) can increase clobazam metabolite levels; strong inducers (e.g., rifampin) can decrease efficacy.
* **Hormonal Contraceptives:** Clobazam can decrease the effectiveness of estrogen-containing oral contraceptives (use barrier methods).
## Monitoring
* **Neuro-Psychiatric:** Monitor for new or worsening depression, anxiety, or behavioral changes.
* **Dermatological:** Monitor for rash, blisters, or skin peeling; discontinue immediately if signs of SJS/TEN appear.
* **Respiratory:** Monitor for signs of excessive sedation or respiratory distress, particularly when used with opioids.
## Clinical Pearls
* **Withdrawal:** Avoid abrupt discontinuation to prevent status epilepticus or severe withdrawal symptoms. Taper slowly.
* **Suspension:** Shake the oral suspension well before use. Use the provided calibrated measuring device.
* **Tolerance:** Anticonvulsant tolerance may develop over time, which may require dose adjustment.
***
**Educational Disclaimer:** This information is for educational purposes only. Clinical practice protocols and patient-specific factors vary. Always verify current prescribing information, package inserts, and institutional guidelines before prescribing or administering medication.
